RegenLab USA

RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holder of over 70 granted patents, covering proprietary blood-processing devices, crosslinked scaffolds, combination products, bone marrow–derived solutions, and bioengineered matrices designed for point-of-care preparation and safe, reproducible use across outpatient and surgical settings. RegenLab has built a modular regenerative product platform that enables tailored solutions across multiple therapeutic areas, notably: A stratified osteoarthritis platform designed to address all Kellgren–Lawrence (“KL”) grades (II to IV) with standardized offerings, including: Arthrovisc, our CE-MDR product utilizing HA-alone syringes; Regenkit, our CE-MDR and FDA cleared product utilizing PRP-only solutions; Cellular Matrix, our CE-MDR product, with a PMA in process, integrating PRP with linear HA for Grade III KL; and RegenMatrix, our pipeline product, integrating PRP with crosslinked HA.